{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:49:48Z","timestamp":1783097388889,"version":"3.54.6"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017154","name":"Tr\u01b0\u1eddng \u0110\u1ea1i h\u1ecdc Duy T\u00e2n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2320-B-039-059"],"award-info":[{"award-number":["NSTC 113-2320-B-039-059"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178049","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:56:14Z","timestamp":1754582174000},"page":"178049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structural equation modelling of nucleotide polymorphisms and pharmacokinetics in direct oral anticoagulant use for stroke and embolism prevention in atrial fibrillation"],"prefix":"10.1016","volume":"1005","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2951-0903","authenticated-orcid":false,"given":"Thi-Phuong-Thao","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8686-8140","authenticated-orcid":false,"given":"Huynh-Thien- Xuan","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2397-0423","authenticated-orcid":false,"given":"Pham-Minh-Khue","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9240-1289","authenticated-orcid":false,"given":"Ngoc-Anh-Tuyet","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh-Nhu","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-2128","authenticated-orcid":false,"given":"Hai-Anh","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-4834","authenticated-orcid":false,"given":"Chin-Chuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178049_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/MJBL.MJBL_71_22","article-title":"A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran","volume":"19","author":"Abd Alridha","year":"2022","journal-title":"Medical Journal of Babylon"},{"key":"10.1016\/j.ejphar.2025.178049_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/genes14061192","article-title":"The distribution of the genotypes of ABCB1 and CES1 polymorphisms in Kazakhstani patients with atrial fibrillation treated with DOAC","volume":"14","author":"Abdrakhmanov","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2025.178049_bib3","first-page":"499","article-title":"Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population","volume":"15","author":"Abdrakhmanov","year":"2024","journal-title":"Caspian J. Int. Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib4","unstructured":"Arno, A., 2023. Faster screening with PICOS-structured eligibility criteria. Covidence URL https:\/\/www.covidence.org\/blog\/faster-screening-with-picos-structured-eligibility-criteria\/(accessed 12.29.24)."},{"key":"10.1016\/j.ejphar.2025.178049_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib6","series-title":"Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions","author":"Bhandari","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178049_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Buuren","year":"2011","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.ejphar.2025.178049_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007113","article-title":"Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients","volume":"13","author":"Campos-Staffico","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178049_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.12970\/2311-052X.2019.07.02","article-title":"Observational study of the inter-individual variability of the plasma concentrations of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) and the effect of rs4148738 polymorphism of ABCB1","volume":"7","author":"Cosmi","year":"2019","journal-title":"Journal of Cardiology and Therapeutics"},{"key":"10.1016\/j.ejphar.2025.178049_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/jcm13092545","article-title":"Role of CES1 and ABCB1 genetic polymorphisms on functional response to dabigatran in patients with atrial fibrillation","volume":"13","author":"Cumitini","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003735","article-title":"Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF\u2010TIMI 48 trial","volume":"5","author":"Eisen","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2025.178049_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102181","article-title":"Atrial fibrillation and stroke: state-Of-The-Art and future directions","volume":"49","author":"Elsheikh","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178049_bib13","series-title":"Exploratory Factor Analysis","author":"Fabrigar","year":"2012"},{"key":"10.1016\/j.ejphar.2025.178049_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.20996\/1819-6446-2024-2941","article-title":"Effect of CYP3A4\/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis","volume":"20","author":"Fedina","year":"2024","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178049_bib15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.20996\/1819-6446-2022-12-02","article-title":"Effect of ABCB1 gene carriage and drug-drug interactions on apixaban and rivaroxaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis","volume":"18","author":"Fedina","year":"2022","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178049_bib16","series-title":"Hands-on Machine Learning with Scikit-Learn, Keras, and Tensorflow: Concepts, Tools, and Techniques to Build Intelligent Systems","author":"G\u00e9ron","year":"2019"},{"key":"10.1016\/j.ejphar.2025.178049_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43179-7","article-title":"Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban","volume":"13","author":"Han","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178049_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.178049_bib31","series-title":"Applied Logistic Regression","first-page":"313","article-title":"Logistic regression models for the analysis of correlated data","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.ejphar.2025.178049_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1290785","article-title":"Construction of a risk scoring system using clinical factors and RYR2 polymorphisms for bleeding complications in patients on direct oral anticoagulants","volume":"14","author":"Jang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178049_bib20","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178049_bib21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/bcp.14646","article-title":"The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation","volume":"87","author":"Ji","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178049_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib24","article-title":"Principal component analysis: a review and recent developments","volume":"374","author":"Jolliffe","year":"2016","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"key":"10.1016\/j.ejphar.2025.178049_bib25","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2147\/DDDT.S417096","article-title":"ABCG2 gene polymorphisms may affect the bleeding risk in patients on apixaban and rivaroxaban","volume":"17","author":"Kim","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"JACC"},{"key":"10.1016\/j.ejphar.2025.178049_bib59","series-title":"Principles and Practice of Structural Equation Modeling","article-title":"Principles and practice of structural equation modeling","author":"Kline","year":"2016"},{"key":"10.1016\/j.ejphar.2025.178049_bib27","first-page":"43","article-title":"Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. PharmacoEcon","volume":"11","author":"Kryukov","year":"2018","journal-title":"Pers. Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cpt.2316","article-title":"Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users","volume":"110","author":"L\u00e4hteenm\u00e4ki","year":"2021","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178049_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cpt.2316","article-title":"Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users","volume":"110","author":"L\u00e4hteenm\u00e4ki","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib30","article-title":"Mutant CYP3A4\/5 correlated with clinical outcomes by affecting rivaroxaban pharmacokinetics and pharmacodynamics in patients with atrial fibrillation","author":"Li","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2025.178049_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.20996\/1819-6446-2020-10-05","article-title":"New pharmacogenetic markers to predict the risk of bleeding during taking of direct oral anticoagulants","volume":"16","author":"Mirzaev","year":"2020","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178049_bib33","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1080\/02664763.2023.2220087","article-title":"Book review: Finding groups in data: an introduction to cluster analysis, authored by Leonard Kaufman and Peter","volume":"51","author":"Modak","year":"2024","journal-title":"J. Rousseeuw. J. Appl. Stat."},{"key":"10.1016\/j.ejphar.2025.178049_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-022-03424-w","article-title":"Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation","volume":"79","author":"Nakagawa","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178049_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bcpt.13488","article-title":"Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation","volume":"128","author":"Nakagawa","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178049_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040622312438934","article-title":"Novel anticoagulants in atrial fibrillation stroke prevention","volume":"3","author":"Norgard","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.ejphar.2025.178049_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000001710","article-title":"The effect of ABCB1 and CES1 polymorphisms on plasma levels of dabigatran and risk of hemorrhagic complications in ischemic stroke patients","volume":"31","author":"Ol\u0161erov\u00e1","year":"2024","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178049_bib39","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2025.178049_bib40","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Par\u00e9","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178049_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/jpm11010037","article-title":"Pharmacogenetics of direct oral anticoagulants: a systematic review","volume":"11","author":"Raymond","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030133","article-title":"An exploratory association analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with non-major bleeding risk in atrial fibrillation patients treated with dabigatran or apixaban","volume":"10","author":"Rosian","year":"2020","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib44","series-title":"Lavaan: Latent Variable Analysis","author":"Rosseel","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178049_bib46","series-title":"Rubinstein RY, Kroese DP. Wiley series in probability and statistics","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/9781118631980.ch7","article-title":"Sensitivity analysis and Monte Carlo optimization","author":"Rubinstein","year":"2016"},{"key":"10.1016\/j.ejphar.2025.178049_bib45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178049_bib47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.20996\/1819-6446-2023-2970","article-title":"Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease","volume":"19","author":"Shatalova","year":"2023","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178049_bib48","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s11033-019-04722-w","article-title":"Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis","volume":"46","author":"Sychev","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178049_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/FPC.0000000000000483","article-title":"Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice","volume":"32","author":"Sychev","year":"2022","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.ejphar.2025.178049_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.15690\/vramn7807","article-title":"Personalization of anticoagulant therapy with direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease based on pharmacogenetic testing. Vestn. Ross","volume":"78","author":"Sychev","year":"2023","journal-title":"Akad. Med. Nauk"},{"key":"10.1016\/j.ejphar.2025.178049_bib51","article-title":"Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178049_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40246-023-00506-3","article-title":"The impact of ABCB1, CYP3A4\/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation","volume":"17","author":"Wu","year":"2023","journal-title":"Hum. Genom."},{"key":"10.1016\/j.ejphar.2025.178049_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1263","article-title":"Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: a multicentre prospective cohort study","volume":"13","author":"Xiang","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1104","article-title":"Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: a nationwide multicentre prospective cohort study","volume":"12","author":"Xiang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.178049_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091889","article-title":"Association between genetic polymorphisms and bleeding in patients on direct oral anticoagulants","volume":"14","author":"Yoon","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178049_bib42","unstructured":"Center for Drug Evaluation Research. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration; 2024. URL https:\/\/www.fda.gov\/drugs\/science-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling. (accessed 12.29.24)."},{"key":"10.1016\/j.ejphar.2025.178049_bib38","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., n.d. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. URL https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 12.29.24)."},{"key":"10.1016\/j.ejphar.2025.178049_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bdd.2327","article-title":"Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation","volume":"43","author":"Zhang","year":"2022","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejphar.2025.178049_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-022-02910-4","article-title":"The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ejphar.2025.178049_bib56","doi-asserted-by":"crossref","unstructured":"Yu, Guangchuang, and Qing-Yu He. 2016. \u201cReactomePA: An r\/Bioconductor Package for Reactome Pathway Analysis and Visualization.\u201d Molecular BioSystems 12 (2): 477\u201379. https:\/\/doi.org\/10.1039\/C5MB00663E.","DOI":"10.1039\/C5MB00663E"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:31:54Z","timestamp":1772796714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"alternative-id":["S0014299925008039"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178049","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural equation modelling of nucleotide polymorphisms and pharmacokinetics in direct oral anticoagulant use for stroke and embolism prevention in atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178049"}}